熱門資訊> 正文
Olema在乳腺癌候选人Palazestrant的数据中下降了30%
2025-10-20 21:16
- Olema Pharmaceuticals (NASDAQ:OLMA) plunged 30% in pre-market trading Monday after announcing new data from a phase 1b/2 trial of palazestrant in breast cancer.
- The candidate is under investigation in combination with Novartis' (NVS) Kisqali (ribociclib) for HR+/HER- advanced or metastatic breast cancer.
- Patients received either 90 mg or 120 mg of palazestrant plus 600 mg Kisqali daily.
- Results showed that with a median follow-up of 10.8 months, those in the 90 mg group did not reach progression-free survival. Those in the 120 mg cohort, with a median follow-up of over 19 months, median PFS was 15.5 months.
- Olema said that palazestrant was well tolerated with most treatment-emergent adverse events being grade 1 or 2.
More on Olema Pharmaceuticals
- Biggest stock movers Monday: PLUG, RANI, and more
- Goldman's 48 potential M&A candidates
- Seeking Alpha’s Quant Rating on Olema Pharmaceuticals
- Historical earnings data for Olema Pharmaceuticals
- Financial information for Olema Pharmaceuticals
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
